Increase of EBV-specific T cells after lymphodepletion and EBV-specific CTL infusion. (A) The EBV-specific T-cell precursor frequency in patients' PBMCs was determined with IFN-γ ELISPOT assays using autologous LCL. (B) EBV peptide-specific T-cell responses were compared with CMVpp65-specific T-cell responses with IFN-γ ELISPOT assays using peptides (*EBV peptide-specific T cells before mAb vs 8 weeks, P = .001; **CMVpp65-specific T cells before mAb vs 8 weeks, P not significant).